Premium
Dalbavancin: A Novel Lipoglycopeptide Antibacterial
Author(s) -
Pope Scott D.,
Roecker Andrew M.
Publication year - 2006
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.26.7.908
Subject(s) - dalbavancin , linezolid , staphylococcus aureus , vancomycin , tolerability , clinical trial , medicine , microbiology and biotechnology , dosing , antimicrobial , pharmacology , biology , adverse effect , bacteria , genetics
Dalbavancin is a new lipoglycopeptide antibacterial possessing in vitro activity against a variety of gram‐positive pathogens. Against methicillin‐susceptible and methicillin‐resistant Staphylococcus aureus , it has demonstrated favorable minimum inhibitory concentration ranges compared with those of currently available agents. Dalbavancin is highly protein bound (> 90%), which may contribute to its prolonged half‐life of 149–300 hours. Because of this long half‐life, once‐weekly dosing strategies have been used in clinical trials. Efficacy and tolerability have been demonstrated in a wide variety of animal infection models. Clinical success and safety have been shown in phase II and III trials for skin and soft‐tissue infections and a phase II trial for catheter‐related bloodstream infections. In these trials with vancomycin, linezolid, and various β‐lactams as comparators, comparable results have been reported. The results of further phase III trials are anxiously awaited and will more clearly define the clinical role of this novel agent.